Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Hemgenix's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Hemgenix. Showing past 6 months and next 12 months · 18 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Hemgenix | CSL Limited | AAV gene therapy | Approved | 0 | ||||
| A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B | Pfizer | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) | CSL Behring | — | Phase 3 | — | — | — | — | — |
| Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively | Pfizer | — | Phase 3 | — | — | — | — | — |
| Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug | Shanghai Xinzhi BioMed Co., Ltd. | — | PHASE2/PHASE3 | — | — | — | — | — |
| Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B | Pfizer | — | Phase 2 | — | — | — | — | — |
| A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients | Institute of Hematology & Blood Diseases Hospital, China | — | PHASE1/PHASE2 | — | — | — | — | — |
| Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" | Bayer | — | PHASE1/PHASE2 | — | — | — | — | — |
| Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B | Baxalta now part of Shire | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B | Regeneron Pharmaceuticals | — | PHASE1/PHASE2 | — | — | — | — | — |